A single-center, open-labeled, randomized, 6-month, parallel-group study to assess the safety and efficacy of allogeneic cultured keratinocyte sheet transplantation for deep second-degree burn wounds: rationale and design of phase I/II clinical trial

Shayan Farzanbakhsh,Mohammad Amin Shahrbaf,Hoda Madani,Mostafa Dahmardei,Bahareh Sadri,Massoud Vosough,Bahareh Sadri and Massoud Vosough
DOI: https://doi.org/10.1186/s13063-024-08070-4
IF: 2.728
2024-04-02
Trials
Abstract:Burn-related injuries are a major global health issue, causing 180,000 deaths per year. Early debridement of necrotic tissue in association with a split-thickness skin graft is usually administered for some of the 2nd- and 3rd-degree injuries. However, this approach can be complicated by factors such as a lack of proper donor sites. Artificial skin substitutes have attracted much attention for burn-related injuries. Keratinocyte sheets are one of the skin substitutes that their safety and efficacy have been reported by previous studies.
medicine, research & experimental
What problem does this paper attempt to address?
### Problems the Paper Aims to Address This paper aims to evaluate the safety and efficacy of allogeneic cultured keratinocyte sheet transplantation in deep second-degree burn wounds and designs a single-center, open-label, randomized, 6-month parallel group study. Specifically, the study includes two consecutive clinical trial phases: 1. **Phase I**: A non-randomized open-label trial involving 5 patients, aimed at assessing the safety and feasibility of the keratinocyte sheets. 2. **Phase II**: A randomized open-label trial involving 35 patients, aimed at further evaluating the safety and efficacy of the product and comparing it with autologous skin grafts and conventional treatment methods. The primary objective of the study is to design and implement a cell-based skin substitute in Iran for the first time and propose registering the product as a ready-to-use product for burn management. Additionally, wound healing is evaluated through multiple follow-up points, including on day 3, day 7, day 10, day 14, day 21, and day 28, with final evaluations at 3 months and 6 months post-operation.